Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIM1 | P11309 | 15/20 | 1.00 |
| ▸ | PIM2 | Q9P1W9 | 13/20 | 1.00 |
| ▸ | FLT3 | P36888 | 2/20 | 1.00 |
| ▸ | PIM3 | Q86V86 | 1/20 | 1.00 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | RECQL | P46063 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.47 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.47 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.47 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | MMP2 | P08253 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.47 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.47 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.43 |
| ▸ | MET | P08581 | 2/20 | 0.43 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29354565 | 1.00 | PIM1 (1.00) | PIM1PIM2FLT3PIM3MEN1 | |
| SCHEMBL706812 | 1.00 | PIM1 (1.00) | PIM1PIM2FLT3PIM3MEN1 | |
| SCHEMBL10091584 | 1.00 | PIM1 (1.00) | PIM1PIM2FLT3PIM3MEN1 | |
| SCHEMBL31633433 | 1.00 | PIM1 (1.00) | PIM1PIM2FLT3PIM3MEN1 | |
| Hydrochloric Acid SCHEMBL29353760 | 0.99 | PIM1 (0.98) | PIM1PIM2FLT3PIM3MEN1 | |
| Hydrochloric Acid SCHEMBL31090685 | 0.98 | PIM1 (0.97) | PIM1PIM2FLT3PIM3MEN1 | |
| SCHEMBL10091583 | 0.97 | PIM1 (0.94) | PIM1PIM2FLT3PIM3MEN1 | |
| SCHEMBL31434436 | 0.93 | PIM1 (0.87) | PIM1PIM2FLT3PIM3MEN1 | |
| SCHEMBL10091766 | 0.92 | PIM1 (0.86) | PIM1PIM2FLT3PIM3MEN1 | |
| SCHEMBL31434336 | 0.91 | PIM1 (0.84) | PIM1PIM2FLT3PIM3ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3432886-B1 | PIM KINASE INHIBITORS IN COMBINATION WITH RNA SPLICING MODULATORS/INHIBITORS FOR TREATMENT OF CANCERS | UNIV MARYLAND (US) | 2021-06-02 | — | — | EP | claimed |
| US-10842785-B2 | PIM kinase inhibitors in combination with RNA splicing modulators/inhibitors for treatment of cancers | THE UNIVERSITY OF MARYLAND, BALTIMORE COUNTY (US) | 2020-11-24 | — | — | US | claimed |
| US-20200230125-A1 | PIM KINASE INHIBITORS IN COMBINATION WITH AUTOPHAGY INHIBITORS FOR TREATMENT OF CANCERS | UNIV MARYLAND (US) | 2020-07-23 | — | — | US | claimed |
| US-20200046689-A1 | PIM KINASE INHIBITORS IN COMBINATION WITH RNA SPLICING MODULATORS/INHIBITORS FOR TREATMENT OF CANCERS | UNIV MARYLAND (US) | 2020-02-13 | — | — | US | claimed |
| WO-2019070777-A2 | PIM KINASE INHIBITORS IN COMBINATION WITH AUTOPHAGY INHIBITORS FOR TREATMENT OF CANCERS | UNIVERSITY OF MARYLAND, BALTIMORE COUNTY (US) | 2019-04-11 | — | — | WO | claimed |
| US-20190076416-A1 | PIM KINASE INHIBITORS IN COMBINATION WITH RNA SPLICING MODULATORS/INHIBITORS FOR TREATMENT OF CANCERS | UNIV MARYLAND (US) | 2019-03-14 | — | — | US | claimed |
| EP-3432886-A1 | PIM KINASE INHIBITORS IN COMBINATION WITH RNA SPLICING MODULATORS/INHIBITORS FOR TREATMENT OF CANCERS | University of Maryland, Baltimore County (US) | 2019-01-30 | — | — | EP | claimed |
| WO-2017165495-A1 | PIM KINASE INHIBITORS IN COMBINATION WITH RNA SPLICING MODULATORS/INHIBITORS FOR TREATMENT OF CANCERS | UNIVERSITY OF MARYLAND, BALTIMORE COUNTY (US) | 2017-09-28 | — | — | WO | claimed |
| US-11389440-B2 | PIM kinase inhibitors in combination with autophagy inhibitors for treatment of cancers | UNIVERSITY OF MARYLAND, BALTIMORE COUNTY (US) | 2022-07-19 | — | — | US | disclosed |
| EP-3432886-B1 | PIM KINASE INHIBITORS IN COMBINATION WITH RNA SPLICING MODULATORS/INHIBITORS FOR TREATMENT OF CANCERS | UNIV MARYLAND (US) | 2021-06-02 | — | — | EP | disclosed |
| US-10842785-B2 | PIM kinase inhibitors in combination with RNA splicing modulators/inhibitors for treatment of cancers | THE UNIVERSITY OF MARYLAND, BALTIMORE COUNTY (US) | 2020-11-24 | — | — | US | disclosed |
| US-20200230125-A1 | PIM KINASE INHIBITORS IN COMBINATION WITH AUTOPHAGY INHIBITORS FOR TREATMENT OF CANCERS | UNIV MARYLAND (US) | 2020-07-23 | — | — | US | disclosed |
| US-20200046689-A1 | PIM KINASE INHIBITORS IN COMBINATION WITH RNA SPLICING MODULATORS/INHIBITORS FOR TREATMENT OF CANCERS | UNIV MARYLAND (US) | 2020-02-13 | — | — | US | disclosed |
| US-20190076416-A1 | PIM KINASE INHIBITORS IN COMBINATION WITH RNA SPLICING MODULATORS/INHIBITORS FOR TREATMENT OF CANCERS | UNIV MARYLAND (US) | 2019-03-14 | — | — | US | disclosed |
| WO-2017165495-A1 | PIM KINASE INHIBITORS IN COMBINATION WITH RNA SPLICING MODULATORS/INHIBITORS FOR TREATMENT OF CANCERS | UNIVERSITY OF MARYLAND, BALTIMORE COUNTY (US) | 2017-09-28 | — | — | WO | disclosed |
| US-20120190669-A1 | OXINDOLE COMPOUNDS | CYLENE PHARMACEUTICALS, INC. (US) | 2012-07-26 | — | — | US | disclosed |
| US-8124649-B2 | Oxindole compounds | CYLENE PHARMACEUTICALS, INC. (US) | 2012-02-28 | — | — | US | disclosed |
| EP-2307421-A1 | OXINDOLE COMPOUNDS | Cylene Pharmaceuticals, Inc. (US) | 2011-04-13 | — | — | EP | disclosed |
| US-20100041635-A1 | OXINDOLE COMPOUNDS | CYLENE PHARMACEUTICALS, INC. | 2010-02-18 | — | — | US | disclosed |
| WO-2010002933-A1 | OXINDOLE COMPOUNDS | CYLENE PHARMACEUTICALS, INC. (US) | 2010-01-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100041635-A1 | OXINDOLE COMPOUNDS | FLT3, PIM1, PIM2 | PIM1 2/4885PIM2 3/4885FLT3 1/4885 |
| US-20120190669-A1 | OXINDOLE COMPOUNDS | FLT3, PIM1, PIM2 | PIM1 2/4885PIM2 3/4885FLT3 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.